BOSTON, November 3, 2021 – GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the closing of a Series A financing
GRO Biosciences Inc. wants to make a giant sector in the pharmaceutical industry even larger. The spinout from the lab of Harvard Medical School geneticist George Church aims to make protein drugs more versatile and effective